BioLineRx Ltd. (NASDAQ:BLRX) Sees Significant Increase in Short Interest

BioLineRx Ltd. (NASDAQ:BLRX) saw a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 179,200 shares, an increase of 28.7% from the August 31st total of 139,200 shares. Based on an average daily trading volume, of 270,600 shares, the short-interest ratio is currently 0.7 days.

Analysts Set New Price Targets

Separately, StockNews.com raised BioLineRx from a “sell” rating to a “hold” rating in a research note on Monday, June 3rd.

BioLineRx Trading Down 1.6 %

Shares of NASDAQ BLRX traded down $0.01 during midday trading on Friday, hitting $0.62. The company’s stock had a trading volume of 145,924 shares, compared to its average volume of 333,238. The company has a current ratio of 1.61, a quick ratio of 1.49 and a debt-to-equity ratio of 1.34. The business’s 50 day moving average is $0.69 and its two-hundred day moving average is $0.72. BioLineRx has a 12-month low of $0.51 and a 12-month high of $2.03. The firm has a market cap of $49.56 million, a P/E ratio of -0.82 and a beta of 1.46.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09. The firm had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $3.93 million. As a group, equities research analysts expect that BioLineRx will post -0.25 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioLineRx stock. CVI Holdings LLC acquired a new position in BioLineRx Ltd. (NASDAQ:BLRX) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 815,683 shares of the biotechnology company’s stock, valued at approximately $462,000. CVI Holdings LLC owned approximately 1.02% of BioLineRx at the end of the most recent reporting period. 1.56% of the stock is currently owned by institutional investors and hedge funds.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.